[Control of arterial pressure in diabetic nephropathy].
Luño
J
J
Servicio de Nefrología, Hospital General Universitario Gregorio Marañón Dr. Esquerdo 46 28007 Madrid. joseluno@terra.es
García de Vinuesa
S
S
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000328:Adult; D000419:Albuminuria / Q000209:etiology / Q000503:physiopathology; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects / Q000502:physiology; D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control; D002648:Child; D002986:Clinical Trials as Topic; D003922:Diabetes Mellitus, Type 1 / Q000150:complications; D003924:Diabetes Mellitus, Type 2 / Q000150:complications* / Q000517:prevention & control; D003928:Diabetic Nephropathies / Q000150:complications* / Q000503:physiopathology / Q000517:prevention & control; D018450:Disease Progression; D006801:Humans; D006973:Hypertension / Q000150:complications* / Q000188:drug therapy; D006977:Hypertension, Renal / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology; D007333:Insulin Resistance / Q000502:physiology; D007677:Kidney Function Tests; D011236:Prediabetic State / Q000188:drug therapy* / Q000503:physiopathology; D012084:Renin-Angiotensin System / Q000187:drug effects / Q000502:physiology*; D012307:Risk Factors
D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents